Methods for plant transformation using spectinomycin selection
The present invention relates to methods and compositions for transforming soybean, corn, cotton, or canola explants using spectinomycin as a selective agent for transformation of the explants. The method may further comprise treatment of the explants with cytokinin during the transformation and regeneration process.
1. A method for producing a transgenic plant containing at least two heterologous nucleic acid sequences, comprising:
(a) providing an explant comprising a first heterologous nucleic acid sequence that confers resistance to an herbicide, an aminoglycoside, or hygromycin;
(b) inoculating the explant with Agrobacterium comprising a vector which comprises a second heterologous nucleic acid sequence comprising a selectable marker gene conferring spectinomycin resistance;
(c) co-cultivating the explant with the Agrobacterium to obtain an explant that exhibits spectinomycin resistance; and
(d) regenerating the explant that exhibits spectinomycin resistance into a transgenic plant containing at least the two heterologous nucleic acid sequences;
wherein the explant is treated with a cytokinin at least during steps (b) and (c).
2. The method of claim 1 , wherein the explant comprises an embryonic meristem.
3. The method of claim 1 , wherein the first heterologous nucleic acid sequence confers resistance to glyphosate, bialaphos, phosphinothricin, Basta, glufosinate, 2,4-D, kanamycin, an acetyl-coA carboxylase inhibitor, an oxygen radical generator, or dicamba.
4. The method of claim 1 , wherein the explant is a soybean, corn, cotton, or canola explant.
5. The method of claim 1 , wherein the explant is a soybean or cotton explant.
6. The method of claim 1 , wherein the transgenic plant arises from transformation of a meristem that results in transformation of germline tissue.
7. The method of claim 1 , wherein the resulting plant is non-chimeric.
8. The method of claim 1 , wherein the resulting plant is chimeric.
9. The method of claim 1 , wherein the cytokinin is selected from the group consisting of thidiazuron, BAP (6-Benzylaminopurine), kinetin, CPPU (N-(2-Chloro-4-pyridyl)-N′-phenylurea), 2iP (6-(y,y-Dimethylallylamino) purine), Zeatin, Zeatin-riboside, Adenine, and TIBA (2,3,5-Triiodobenzoic acid).
10. The method of claim 1 , further comprising treatment of the explant with a cytokinin prior to step (b).